Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Donor-specific anti-HLA antibodies in unrelated hematopoietic cell transplantation for non-malignant disorders

Bone Marrow Transplantation volume 54, pages 494–496 (2019)Cite this article

Subjects

To the Editor:

The role of pre-existing donor-specific anti-human leukocyte antigen antibodies (HLA-DSA) in hematopoietic cell transplantation (HCT) is the subject of much debate, reflecting the increasing feasibility of successful transplantation across HLA mismatch barriers. In our study of patients transplanted for non-malignant disease (NMD), HLA-mismatching increased the risk of graft failure and was 2–3-fold higher when compared to patients with malignancies [1]. After adjustment for other factors, the odds ratio for primary or secondary graft failure for 7/8 and 6/8 matched pairs was 2.81 (1.74–4.54; p < 0.0001) and 2.22 (1.26–3.97; p = 0.006), respectively.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Notes

  1. *Corporate Members.

References

  1. Horan J, Wang T, Haagenson M, Spellman SR, Dehn J, Eapen M, et al. Evaluation of HLA matching in unrelated hematopoietic stem cell transplantation for nonmalignant disorders. Blood. 2012;120:2918–24.

    Article  CAS  Google Scholar 

  2. Pei R, Lee JH, Shih NJ, Chen M, Terasaki PI. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation. 2003;75:43–9.

    Article  CAS  Google Scholar 

  3. Chen G, Sequeira F, Tyan DB. Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. Hum Immunol. 2011;72:849–58. https://doi.org/10.1016/j.humimm.2011.07.001.

    Article  CAS  PubMed  Google Scholar 

  4. Spellman S, Bray R, Rosen-Bronson S, Haagenson M, Klein J, Flesch S, et al. The detection of donor directed, HLA-specific alloantibodies in recipients of unrelated hematopoietic cell transplantation is predictive of graft failure. Blood. 2010;115:2704–8.

    Article  CAS  Google Scholar 

  5. Ciurea SO, Thall PF, Wang X, Wang SA, Hu Y, Cano P, et al. Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation. Blood. 2011;118:5957–64.

    Article  CAS  Google Scholar 

  6. Ruggeri A, Rocha V, Masson E, Labopin M, Cunha R, Absi L, et al. Impact of donor-specific anti-HLA antibodies on graft failure and survival after reduced intensity conditioning-unrelated cord blood transplantation. Haematologica. 2013;98:1154–60.

    Article  Google Scholar 

  7. Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012;367:1487–96.

    Article  CAS  Google Scholar 

  8. Margolis D, Camitta B, Pietryga D, Keever-Taylor C, Baxter-Lowe LA, Pierce K, et al. Unrelated donor bone marrow transplantation to treat severe aplastic anaemia in children and young adults. Br J Haematol. 1996;94:65–72.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The CIBMTR is supported primarily by Public Health Service Grant/Cooperative Agreement 5U24-CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant/Cooperative Agreement 5U10HL069294 from NHLBI and NCI; a contract HHSH250201200016C with Health Resources and Services Administration (HRSA/DHHS); two Grants N00014-15-1-0848 and N00014-16-1-2020 from the Office of Naval Research; and grants from *Actinium Pharmaceuticals, Inc.; Alexion; *Amgen, Inc.; Anonymous donation to the Medical College of Wisconsin; Astellas Pharma US; AstraZeneca; Atara Biotherapeutics, Inc.; Be the Match Foundation; *Bluebird Bio, Inc.; *Bristol Myers Squibb Oncology; *Celgene Corporation; Cellular Dynamics International, Inc.; Cerus Corporation; *Chimerix, Inc.; Fred Hutchinson Cancer Research Center; Gamida Cell Ltd.; Genentech, Inc.; Genzyme Corporation; Gilead Sciences, Inc.; Health Research, Inc. Roswell Park Cancer Institute; HistoGenetics, Inc.; Incyte Corporation; Janssen Scientific Affairs, LLC; *Jazz Pharmaceuticals, Inc.; Jeff Gordon Children’s Foundation; The Leukemia & Lymphoma Society; Medac, GmbH; MedImmune; The Medical College of Wisconsin; *Merck & Co, Inc.; *Mesoblast; MesoScale Diagnostics, Inc.; *Miltenyi Biotec, Inc.; National Marrow Donor Program; Neovii Biotech NA, Inc.; Novartis Pharmaceuticals Corporation; Onyx Pharmaceuticals; Optum Healthcare Solutions, Inc.; Otsuka America Pharmaceutical, Inc.; Otsuka Pharmaceutical Co, Ltd.—Japan; PCORI; Perkin Elmer, Inc.; Pfizer, Inc; *Sanofi US; *Seattle Genetics; *Spectrum Pharmaceuticals, Inc.; St. Baldrick’s Foundation; *Sunesis Pharmaceuticals, Inc.; Swedish Orphan Biovitrum, Inc.; Takeda Oncology; Telomere Diagnostics, Inc.; University of Minnesota; and *Wellpoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA) or any other agency of the U.S. Government.Footnote 1

Author contributions

AW, MFV, SJL, DT, and SRS designed the study; GC performed HLA-DSA testing; TW and MDH performed statistical analyses; AW, MFV, SJL, and SRS interpreted analysis; AW and SJL wrote the paper; TW, MDH, GC, KF, JH, KH, DT, MV, SRS, and MFV critically reviewed and revised the paper.

Author information

Authors and Affiliations

  1. Fred Hutchinson Cancer Research Center, Seattle, WA, USA

    Ann Woolfrey & Stephanie J. Lee

  2. Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI, USA

    Tao Wang

  3. Center for International Blood and Marrow Transplant Research, Minneapolis, MN, USA

    Michael D. Haagenson & Stephen R. Spellman

  4. Stanford School of Medicine, Stanford, CA, USA

    Ge Chen & Marcelo Fernandez-Vina

  5. Institute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany

    Katharina Fleischhauer

  6. Emory University, Atlanta, GA, USA

    John Horan

  7. Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Katharine Hsu

  8. University of Colorado-Children’s Hospital, Aurora, CO, USA

    Michael Verneris

Authors
  1. Ann Woolfrey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tao Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stephanie J. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael D. Haagenson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ge Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Katharina Fleischhauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. John Horan
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Katharine Hsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Michael Verneris
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Stephen R. Spellman
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Marcelo Fernandez-Vina
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephen R. Spellman.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Woolfrey, A., Wang, T., Lee, S.J. et al. Donor-specific anti-HLA antibodies in unrelated hematopoietic cell transplantation for non-malignant disorders. Bone Marrow Transplant 54, 494–496 (2019). https://doi.org/10.1038/s41409-018-0334-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-018-0334-y

Keywords

This article is cited by

Search

Advanced search

Quick links